ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

FLAGYL
Bacterial infections
Protozoal infections
Vaginal infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

FLAGYL Rx

Generic Name and Formulations:
Metronidazole 250mg, 500mg; tabs.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for FLAGYL:

Susceptible anaerobic infections, including intraabdominal, skin and skin structures, gynecologic, bacterial septicemia, bone and joint, CNS, lower respiratory tract, endocarditis.

Adult:

7.5mg/kg every 6hrs for 7–10 days; max 4g/24hrs. Serious infections: parenteral form usually used first. Bone/joint, lower respiratory tract, endocardium infections: may need to treat longer. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Children:

Not established.

Contraindications:

Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol or propylene glycol containing-products during or at least 3 days after treatment.

Warnings/Precautions:

Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. Risk of severe/fatal hepatotoxicity in Cockayne Syndrome; obtain LFTs (at baseline, within first 2–3 days after initiation, frequently during therapy, and after completion); discontinue if elevated. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy. Nursing mothers: not recommended.

See Also:

FLAGYL 375

Metronidazole Injection

Pharmacological Class:

Nitroimidazole.

Interactions:

See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. May interfere with serum chemistry tests.

Adverse Reactions:

Nausea, headache, anorexia, vomiting, diarrhea, epigastric distress, abdominal cramping, constipation, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.

How Supplied:

Tabs—50, 100; Caps 375mg—50; IV—contact supplier

Indications for FLAGYL:

Amebic dysentery. Amebic liver abscess.

Adult:

Give 3 times daily for 5–10 days. Dysentery: 750mg. Abscess: 500mg or 750mg. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Children:

35–50mg/kg/24hrs in 3 divided doses for 10 days. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Contraindications:

Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol or propylene glycol containing-products during or at least 3 days after treatment.

Warnings/Precautions:

Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. Risk of severe/fatal hepatotoxicity in Cockayne Syndrome; obtain LFTs (at baseline, within first 2–3 days after initiation, frequently during therapy, and after completion); discontinue if elevated. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy. Nursing mothers: not recommended.

See Also:

FLAGYL 375

Pharmacological Class:

Nitroimidazole.

Interactions:

See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. May interfere with serum chemistry tests.

Adverse Reactions:

Nausea, headache, anorexia, vomiting, diarrhea, epigastric distress, abdominal cramping, constipation, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.

How Supplied:

Tabs—50, 100; Caps 375mg—50

Indications for FLAGYL:

Trichomoniasis.

Adult:

250mg 3 times daily for 7 days. Or, if patient is not pregnant, 2g in 1–2 divided doses on same day. Before repeating course, reconfirm diagnosis and allow 4–6 wks between courses. Treat consorts also. Severe hepatic impairment: reduce dose by 50%. Hemodialysis: consider dose supplementation after session.

Children:

Not established.

Contraindications:

Pregnancy (1st trimester for trichomoniasis). Within 2 weeks of disulfiram (possible psychotic reactions). Concomitant alcohol or propylene glycol containing-products during or at least 3 days after treatment.

Warnings/Precautions:

Discontinue if abnormal neurological symptoms occur. Candidiasis. History of blood dyscrasias. Monitor for leukopenia; do CBCs before, during and after therapy. Risk of severe/fatal hepatotoxicity in Cockayne Syndrome; obtain LFTs (at baseline, within first 2–3 days after initiation, frequently during therapy, and after completion); discontinue if elevated. Hepatic or renal impairment; monitor. Elderly: monitor serum levels. Pregnancy. Nursing mothers: not recommended.

See Also:

FLAGYL 375

FLAGYL ER

Pharmacological Class:

Antiprotozoal/antibacterial.

Interactions:

See Contraindications. May potentiate oral anticoagulants, lithium; monitor. Avoid concomitant busulfan; if needed, adjust busulfan dose and monitor. May be antagonized by phenobarbital, phenytoin, other hepatic enzyme inducers. May impair phenytoin clearance. May be potentiated by cimetidine, other hepatic enzyme inhibitors. IV: may potentiate 5-FU, vecuronium, CYP3A4 substrates (eg, amiodarone, tacrolimus, cyclosporine,carbamazepine, phenytoin, quinidine); monitor. May interfere with serum chemistry tests.

Adverse Reactions:

Nausea, headache, anorexia, vomiting, diarrhea, epigastric distress, abdominal cramping, constipation, metallic taste, dysuria, cystitis; seizures, encephalopathy, optic/peripheral neuropathy, aseptic meningitis.

How Supplied:

Tabs—50, 100; ER—30; Caps 375mg—50

Sign Up for Free e-newsletters